ESTRO 38 - Programme Book & Exhibition Guide

09:30 > Against the motion D. Verellen (Belgium) 09:45 > Discussion

SUNDAY 28 APRIL 2019

SYMPOSIUM Radiation-drug combinations on the 2019 horizon 08:45 - 10:00 | Brown 3

This session will focus on pending questions about radiation-drug combinations on the 2019 horizon. First will be pointed out the barriers and the potential solutions to improve the research in this domain, from the preclinical model to the clinical trial designs. Then, speakers will develop the specific questions of Tyrosine Kinase inhibitors and DNA damage response inhibitors in combination with radiation therapy: early data studies and clinical evidence. Finally, several cost-estimates models regarding radiation combined with biomarker-agnostic use of a given drug or with molecularly matched medication will be presented. 08:45 > Barriers and solutions to increase the number of clinical trials of new drug-radiotherapy combinations Speaker: R. Sharma (United Kingdom) 09:03 > Radiation and TKIs - what is the 2019 evidence? Speaker: C. Belka (Germany) 09:21 > Radiotherapy in combination with DNA damage response inhibitors in 2019: are we any closer to clinical benefit? Speaker: A. Chalmers (United Kingdom) 09:39 > Cost-estimate models for radiation-drug combinations Speaker: A.H. Ree (Norway) Chair: M. Krause (Germany) Co-chair: S. Bockel (France)

SP-0229

SP-0230

SP-0231

SP-0232

SYMPOSIUM Inverse planning in brachytherapy - A one click solution? 08:45 - 10:00 | Brown 2

In brachytherapy (BT) inverse planning can be used for automatic dose optimization. Similar to external beam IMRT treatment planning dose constraints are defined and an optimization algorithm computes the “best” solution. In Particular in prostate low-dose-rate (LDR) and high- dose-rate (HDR) treatment planning inverse planning is commonly used.

SCIENTIFIC PROGRAMME | Programme and Exhibition Guide

110